University of Oxford

What University of Oxford does

The University of Oxford is a self-governing public research university and charitable institution headquartered in Oxford, England, operating through more than 30 colleges and halls. It serves an undergraduate body (23,000+ applicants in 2024), a graduate cohort in which approximately two-thirds are international (38,000+ applicants in 2023), and over 15,000 adult learners per year via Oxford Lifelong Learning. The institution has held the #1 Times Higher Education World University Rankings position for the tenth consecutive year and ranks #4 in QS World University Rankings 2026/2027 with 98.6 points, drawing students from over 170 countries.

Core technology platforms include the proprietary ChAdOx1 adenoviral vector (origin of the Oxford-AstraZeneca COVID-19 vaccine, now extended to Ebola Bundibugyo and malaria candidates with Serum Institute of India), quantum capabilities including squeezed-cat states, first-of-kind quadsqueezing demonstrations on a single trapped ion, and the planned AION-10 atom interferometer for ultralight dark matter detection, plus an AI portfolio spanning the BOLD Lab and SOFAIR Lab (£60M UKRI), OpenBind open-source drug discovery models, an AI-designed CCHF vaccine in Phase 1 trials, an 86%-accurate CT-based heart failure prediction tool, and the UK Cancer Vaccine AI & Supercomputing Project using Dawn and ISAMBARD-AI supercomputers. Oxford University Innovation, its wholly-owned subsidiary, manages technology transfer and spinout equity across RQ Bio ($115M Series A), Wild Bioscience (£45M Series A), Oxford PV, SugaROx, and others.

Revenue is diversified across undergraduate and graduate tuition (over 1,100 graduate scholarships; £11M+ in annual UK bursaries supporting approximately 1 in 4 domestic undergraduates), UK government and UKRI research grants (£60M for AI Labs; £18M UK-PHRST; £1.6B broader UKRI AI Strategy), industry-funded research partnerships including the 10-year Moderna collaboration (20+ trials, 135 UK centres, 14,500+ participants), CEPI funding (up to $8.6M for the Bundibugyo vaccine), philanthropy (Rhodes Trust, Crankstart, Baszucki Group, Aig-Imoukhuede), lifelong learning fees (15,000+ enrolments on 1,000+ courses), licensing and equity from spinouts, and expert witness and consulting services (171+ experts in the Find An Expert database). The institution operates a global footprint spanning DRC, Uganda, India, the US, France, Australia, Switzerland, and others.

Name

University of Oxford

Legal name

University of Oxford

Website

http://ox.ac.uk

Company type

Private

Founded year

1096

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The University of Oxford is a self-governing public research university operating more than 30 colleges in England, delivering undergraduate and graduate programmes, lifelong learning, and proprietary research in vaccines, quantum systems, and AI, commercialised through its Oxford University Innovation subsidiary.

Ownership category

akta.pro rank

Product category

Higher Education

NAICS

Colleges, Universities, and Professional Schools (6113), Educational Support Services (611710)

SIC

Services-Educational Services (8200)

akta.pro primary industry

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

akta.pro secondary industry

Public Research Universities with Comprehensive Graduate & Professional Schools (EDAHAAAF)

Keywords

• Higher education programs
• Academic research services
• Continuing professional development
• Technology transfer licensing
• Industry research partnerships

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Undergraduate and graduate tuition fees: Core recurring revenue from student tuition fees; UK higher education sector generated total income of £53.9 billion in 2024-25, with elite institutions like Oxford posting billion-pound surpluses. Annual fees vary by course (e.g., domestic vs international; undergraduate vs graduate).
2. Government research grants (UKRI): Major government funding via UK Research and Innovation (UKRI); includes £60M for AI labs, £18M for UK-PHRST research arm, and broader £1.6 billion UKRI AI Strategy. Oxford researchers also receive substantial UK government departmental funding (e.g., NIHR for clinical trials).
3. Philanthropy and donations: Fundraising via the Oxford Excellence campaign across climate, health, and society pillars; supported by Rhodes Trust scholarships, Crankstart Scholarship, Aig-Imoukhuede Foundation partnership, and major alumni/donor contributions.
4. Technology transfer, licensing, and spinout equity: Oxford University Innovation (wholly-owned subsidiary) manages technology transfer, consulting activities, and supports spinout companies (e.g., Wild Bioscience, RQ Bio, Oxford PV, SugaROx). Generates licensing royalties and equity returns from successful spin-outs.
5. Continuing/Lifelong learning fees: Oxford Lifelong Learning offers more than 1,000 part-time courses each year with over 15,000 enrolments; revenue from short courses, online qualifications, summer schools, and continuing professional development programs.
6. Consulting and expert witness services: Oxford academics serve as consultants and expert witnesses through Oxford University Innovation's Consulting Services team; Find An Expert database lists 171+ experts for media and external engagements.
7. Industry research partnerships and clinical trial sponsorship: Industry-funded research partnerships including $50M CEPI funding for Moderna, $8.6M CEPI for Oxford ChAdOx1 BDBV Ebola vaccine; 10-year Moderna-UK Government strategic partnership includes over 20 clinical trials across 135 UK centers with 14,500+ participants.
8. Conference and event hosting services: Conferences at Oxford (conference-oxford.com) generates revenue from hosting academic and corporate conferences in college and departmental facilities.

Pricing tiers

Go-to-market motion1 record

Distribution channels8 records

Marketing channels11 records

Core offering

The University of Oxford delivers higher education through more than 50 undergraduate programmes and over 400 graduate courses, organised across more than 30 colleges using a tutorial-based teaching model, and operates the Oxford Lifelong Learning department for adult learners. It conducts academic and applied research across disciplines and commercialises outputs through its wholly-owned subsidiary Oxford University Innovation, which manages technology transfer, licensing, consulting, expert witness engagements, and spinout company formation. Additional revenue comes from conferences, philanthropy, government research grants, and industry research partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Oxford University Innovation: Wholly-owned subsidiary of the University that manages technology transfer and consulting activities, helping Oxford ideas come to life.
• Oxford Sparks
• Oxplore
• Oxford Lifelong Learning
• Bodleian Libraries
• EnSpire Oxford
• Oxford University Press
• Oxford colleges

Products and services

• Undergraduate degrees
• Postgraduate / Graduate degrees
• Oxford Lifelong Learning (Department for Continuing Education)
• Oxplore
• AI, Justice and Rule of Law (UNESCO–Oxford online course)

Quantifiable outcome

• AI persuasion achieved 17.2% donation rate versus 6.4% for human canvassers (2.7x difference)
• +6 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability18 records

Feature9 records

Partnerships

23 partnerships are on record, tiered flagship, core and minor.

• World Health Organization (WHO)flagshipStrategic or Co-development Partner · 24 June 2026Oxford leads Ebola Bundibugyo clinical trial consortium with WHO, DRC National Institute for Biomedical Research, and ALIMA. Trials of MBP134 monoclonal antibody and remdesivir with 500-1,000 participants expected. WHO declared outbreak a Public Health Emergency of International Concern on May 17.
• University College London (UCL)flagshipStrategic or Co-development Partner · 23 June 2026Partner with Oxford on UKRI-EPSRC £60M AI labs scheme. SOFAIR Lab (UCL-led, with Cambridge, Oxford, and Edinburgh) and BOLD Lab (Oxford-led, with Imperial College London) each receive £8M initial funding over six years. Aims to develop next-generation open-source AI technologies.
• Imperial College LondoncoreStrategic or Co-development Partner · 23 June 2026Partner with Oxford on BOLD Lab (hosted by Oxford's Department of Engineering Science) as part of UKRI-EPSRC £60M AI labs scheme. Six-year programme developing more efficient AI learning systems.
• University of CambridgecoreStrategic or Co-development Partner · 23 June 2026Partner with Oxford on SOFAIR Lab (UCL-led) as part of UKRI-EPSRC £60M AI labs scheme. Also collaborated with Oxford, Wellcome Sanger Institute, and Melbourne on loading complete Hepatitis D virus genome onto IBM 156-qubit Heron quantum processor.
• University of EdinburghcoreStrategic or Co-development Partner · 23 June 2026Partner with Oxford on SOFAIR Lab (UCL-led) as part of UKRI-EPSRC £60M AI labs scheme developing next-generation open-source AI technologies.
• Mapp BiopharmaceuticalcoreTechnology or Integration · 23 June 2026San Diego-based Mapp Biopharmaceutical provided doses of experimental antibody drug MBP134 for clinical trials through U.S. Government support. Oxford leads the trial of MBP134 alongside Gilead Sciences antivirals in the WHO-sponsored Bundibugyo Ebola response.
• AnthropiccoreTechnology or Integration · 20 June 2026Oxford University and other institutions found that Anthropic's Claude Opus 4.6 significantly outperformed professional human fundraisers in a study for charity Save the Children, raising nearly 3x as many donations and securing amounts 13% larger on average across 1,000+ conversations.
• Imperial College London (AION collaboration)flagshipStrategic or Co-development Partner · 18 June 2026UK-led AION collaboration led by Imperial College London with Oxford contributing engineering expertise and senior leadership. Builds on 2024-2025 work demonstrating differential noise-cancellation in long-baseline atom interferometers. Plans for 10-metre AION-10 detector at the University of Oxford Beecroft building. Links to MAGIS at Fermilab and AICE at CERN.
• Tinnitus QuestcoreGTM or Marketing Partner · 17 June 2026International patient-driven nonprofit awarded $230,000 grant to University of Oxford study led by Professor Robin Cleveland investigating transcranial ultrasound stimulation (TUS) as non-invasive tinnitus treatment. Tinnitus Quest launched new funding round and second Tinnitus Hackathon (October 27-29 in Dallas, Texas).
• Gates FoundationcoreStrategic or Co-development Partner · 17 June 2026Gates Foundation partnering with local companies in South Africa to scale production of Oxford's postpartum hemorrhage plastic drape following successful clinical trial. Also involved in broader maternal and neonatal health initiatives.
• International AIDS Vaccine Initiative (IAVI)coreStrategic or Co-development Partner · 12 June 2026Co-recipient of CEPI funding for Bundibugyo Ebola vaccine development alongside Moderna and Oxford/Serum Institute; IAVI received up to $3.2M from CEPI for its rVSV-based single-dose vaccine candidate requiring 7-9 months to reach trial readiness.
• Nissan Technical Centre EuropecoreStrategic or Co-development Partner · 10 June 2026Three-year CoRe-SoLiS project (£3.4M total cost, £2.4M from UK Battery Innovation Program) with Nissan, Gelion, and Oxford to develop lithium-sulfur-based solid-state batteries for EVs. Aims to replace nickel and cobalt with cheaper, more widely available sulfur. Commercial prototype targeted FY2027; Nissan targets first solid-state EV in 2028.
• Eisenhower FellowshipscoreGTM or Marketing Partner · 10 June 2026Partners with Oxford's Blavatnik School of Government on the 2027 Global Scholars Program (73rd year), providing fully-funded Master of Public Policy degrees focused on international affairs, democratic governance, cybersecurity, and national security policy. Network of 2,600+ influential leaders.
• ModernaflagshipStrategic or Co-development Partner · 8 June 2026Oxford and Moderna received MHRA authorization for INTERCEPT-Lynch Phase 1/2 cancer vaccine trial (mRNA-4194) for Lynch syndrome. Part of 10-year Moderna-UK Government strategic partnership established 2022 with 20+ clinical trials across 135 UK centers and 14,500+ participants. Moderna also receives up to $50M CEPI funding for Bundibugyo Ebola vaccine.
• Gelion TechnologiescoreStrategic or Co-development Partner · 5 June 2026Anglo-Australian energy storage company partnered with Nissan and Oxford on the CoRe-SoLiS project; £1.6M of grant funding allocated to Gelion's UK subsidiary. Provides proprietary Nano-Encapsulated Sulfur cathode technology for solid-state battery development.
• Basecamp ResearchcoreStrategic or Co-development Partner · 5 June 2026Oxford's Oxford Vaccine Group partnered with Basecamp Research on the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF). First-phase trial under way at the Oxford Vaccine Group to assess safety and immune response in healthy volunteers.
• Serum Institute of IndiaflagshipStrategic or Co-development Partner · 4 June 2026Oxford University and Serum Institute of India partnered to develop and manufacture clinical trial doses of ChAdOx1 BDBV vaccine targeting the Bundibugyo strain of Ebola. CEPI provided $8.6 million in initial funding. SII to mass-produce the vaccine if successful, with potential to scale within a 20-30 day window. Also collaborating on R78C multi-stage malaria vaccine (signed licensing agreement).
• Coalition for Epidemic Preparedness Innovations (CEPI)flagshipStrategic or Co-development Partner · 1 June 2026CEPI committed up to $8.6 million for Oxford/SII Bundibugyo Ebola vaccine development as part of broader $60M funding package across three vaccine candidates (IAVI, Moderna, Oxford). Targets Phase 1 clinical trials within 2-3 months. Prioritised for further evaluation in WHO-coordinated Bundibugyo outbreak response.
• UK-France Strategic Biomedical Alliance in Health and AIflagshipStrategic or Co-development Partner · 29 May 2026UK-France partnership involving Oxford, Université Paris Cité, Institut Pasteur, Diamond Light Source, and Synchrotron Soleil, announced at G7 Digital and Technology Ministerial Summit in Paris. Focuses on women's health research (childbirth complications and endometriosis), supported by £900M UK funding for computing infrastructure linking Bristol's Isambard-AI with France's Genci facility.
• Imperial College London and CNRS (France)coreStrategic or Co-development Partner · 29 May 2026Imperial College London signed separate agreement with France's National Center for Scientific Research (CNRS) to collaborate on metabolism research targeting heart disease, cancer, and neurodegenerative disorders. UK-France biomedical alliance complements the partnership Oxford leads.
• Aig-Imoukhuede FoundationcoreStrategic or Co-development Partner · 15 April 2026Operates AIG Public Leaders Programme delivered in partnership with Oxford's Blavatnik School of Government; five cohorts totalling 300+ African public servants graduated, with most recent cohort of 69 participants.
• UNESCOcoreStrategic or Co-development Partner · 15 April 2026Oxford and UNESCO launched free global online course 'AI, Justice and Rule of Law' for judicial professionals; 12-hour self-paced course with Oxford certification; funded by UNESCO with EU support; English launch April 2026, French and Spanish editions June 2026.
• PolestarminorStrategic or Co-development Partner · 1 March 2026Polestar and Oxford's SDG Impact Lab launched pilot research study (March-July 2026) to scientifically define and measure driving thrill. Six PhD Innovation Fellows analyse brain activity, biometric data, and behavioural responses while driving high-performance Polestar vehicles; testing at Gotland Ring test track in Sweden.

Scale indicators17 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• University of Cambridge: Direct UK-based peer and closest competitor in global rankings, with a similar collegiate research model, comparable spinout ecosystem, and joint research activity with Oxford (e.g., SOFAIR Lab, IBM quantum Heron processor). Both compete for the same talent, grants, and partnerships.
• Imperial College London: Direct UK research peer and partner (BOLD Lab, AION collaboration, UK-France biomedical alliance) competing head-to-head with Oxford in STEM, AI, and clinical research while co-investing in shared national infrastructure.
• University College London (UCL): UK-based research peer and partner on the £60M UKRI AI Labs scheme (SOFAIR Lab) and broader London-based research collaborations. Competes for talent and grants in the same UK funding ecosystem.

Broad incumbents

• Harvard University: Top global research university peer with a much larger endowment; co-founded the edX platform that Oxford engages with. Directly comparable in research scale, brand strength, and ability to spin out companies and commercialise IP.
• Stanford University: Direct global competitor in the QS top-5 and benchmark for tech-transfer and spinout creation in AI and biotech. Stanford's industry-tied research model and Silicon Valley adjacency make it a key reference point for Oxford's commercial translation.
• Massachusetts Institute of Technology (MIT): Top-ranked QS university and global benchmark for engineering, AI, and quantum research. Direct peer in advanced technology research with comparable spinout activity (e.g., quantum computing ecosystem that intersects with Oxford's AION and quantum DNA work).
• ETH Zurich: Top European STEM research university peer; comparable in quantum physics, engineering, and AI research output. Useful benchmark for Oxford's positioning in continental European talent and grant competition.
• California Institute of Technology (Caltech): Top-tier US research peer in physics, quantum, and space sciences, with deep ties to NASA/JPL and federally funded research. Relevant benchmark for Oxford's quantum (AION) and astrophysics research positioning.
• Princeton University: Top US research university with similar undergraduate-tutoring ethos and elite global brand. Comparable in selectivity, research intensity, and ability to attract international talent and external research funding.
• University of California, Berkeley: Top US public research university with comparable scale in AI, biotech, and quantum research. Frequently co-appears with Oxford in global rankings and competes for the same top faculty and graduate students.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/uniofoxford
• YouTubeyoutube.com/oxford
• Facebookfacebook.com/the.university.of.oxford
• LinkedInlinkedin.com/company/oxforduni
• Instagraminstagram.com/oxford_uni
• TikToktiktok.com/@uni.of.oxford

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Oxford